$0.363
-0.069 (-18.97%)收盤時
PRPH 資訊
PRPH 事件
ProPhase Labs Updates on Crown Medical Collections Progress
ProPhase Labs provided a business update regarding its Crown Medical Collections initiative and related strategic activities. The Company reported that its Crown Medical Collections effort continues to advance, with engagement now underway with more than 250 insurance payors. Of these matters, approximately 100 are currently in active settlement discussions, with a number of cases progressing into more advanced stages of negotiation. Based on the level of engagement and progression of discussions, the Company believes current activity is trending in line with its previously communicated recovery framework and internal estimates, and is encouraged by the ongoing development of these discussions. In parallel, the Company is engaged in discussions with institutional capital providers regarding potential financing alternatives, including structures that are expected to be secured by the Company's receivables platform, without recourse to the parent company. These discussions follow extensive third-party diligence conducted on the receivables and related recovery processes. While no assurances can be given that any transaction will be completed, the Company believes the level of diligence completed and the nature of these discussions reflect growing external validation of the underlying asset and may enhance its financial flexibility. Management continues to focus on stabilizing near term liquidity, managing liabilities and vendor relationships, and preserving and advancing key assets, including Nebula Genomics/DNA Complete and the BE-Smart esophageal cancer diagnostic. The Company believes it is beginning to see tangible indicators of progress driven by advancing settlement activity and continued strategic engagement, with current developments tracking in line with Crown Medical's prior guidance to the Company. ProPhase Labs remains focused on execution and expects to provide additional updates in the near future as developments occur.
ProPhase Labs Initiates Sale or Strategic Partnership for BE-Smart
ProPhase Labs announced that it has initiated a potential sale or strategic partnership process for BE-Smart, its clinically validated esophageal cancer risk stratification test, and is advancing its Crown Medical Collections initiative. "We believe BE-Smart represents a differentiated, clinically validated diagnostic that is ready for commercial deployment as an LDT," said Ted Karkus, Chairman and Chief Executive Officer of ProPhase Labs. "By pursuing a sale or strategic partnership, we aim to unlock immediate liquidity, significantly reduce internal development and commercialization costs, and potentially participate in long-term royalty or revenue-sharing streams as adoption expands through a partner's established distribution network."
ProPhase Labs Updates on COVID-19 Testing Receivables Progress
ProPhase Labs provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings. According to Crown Medical: "Crown Medical Collections, in its capacity as special counsel for the collection of accounts receivable, is actively engaged in settlement negotiations with more than 250 insurance payors relating to outstanding ProPhase receivables. Approximately 50 of these matters are presently in advanced settlement posture, with anticipated resolutions expected to close within the next 30 to 90 days. These recoveries are expected to generate substantial proceeds and materially enhance near-term liquidity in support of ongoing operations and an orderly court-supervised restructuring process."
ProPhase Labs Trading Halted, News Pending
ProPhase Labs trading halted, news pending
ProPhase Labs and ABL Sign LOI for Proposed Reverse Merger
ProPhase Labs and Advanced Biological Laboratories entered into a non-binding Letter of Intent regarding a proposed reverse merger transaction pursuant to which ABL would become the majority owner of the combined entity. The LOI reflects preliminary understandings only and does not create any obligation to consummate a transaction, except with respect to customary confidentiality and expense provisions. The Proposed Transaction remains subject to completion of due diligence, negotiation and execution of definitive agreements, regulatory approvals, Nasdaq listing requirements, and other customary closing conditions. While subject to finalization in definitive agreements, the parties have discussed a preliminary, non-binding valuation framework for the legacy ProPhase business that may imply an enterprise value of up to approximately $30M. Under the terms contemplated in the LOI, subject to applicable law, board approvals, and definitive documentation, ProPhase Labs may declare a special cash dividend of up to $109M payable to shareholders of ProPhase Labs common stock as of a record date to be determined. Any such cash distribution would be separate from and not part of the merged operating company. Additionally, all Crown Medical Collections receivables are expected to be carved out for the exclusive benefit of current ProPhase shareholders. This framework represents the preliminary structure, subject to definitive documentation, for the transaction, expressly excludes certain cash distributions, asset carve-outs, and retained liabilities described below, and is subject to change based on due diligence, capitalization adjustments, financing activity, market conditions and final transaction terms. The parties currently anticipate working toward execution of definitive documentation within approximately 60 to 90 days. The Proposed Transaction envisions that ABL shareholders would own approximately 76% of the combined company at closing. Following completion of the merger, a newly established U.S. subsidiary would hold and operate ProPhase's Nebula Genomics platform, BE-Smart Esophageal Cancer Test program, and select consumer health businesses, enabling focused capital allocation and strategic execution. ABL would contribute its global infrastructure, including advanced data processing systems, cloud computing for health data, and financing capabilities. Under the LOI, ProPhase Labs may declare a special cash dividend of up to $10M payable to shareholders of record as of a date to be determined. This distribution would be separate from the merged operating company. Additionally, all Crown Medical Collections receivables are expected to be carved out for the exclusive benefit of current ProPhase shareholders, with anticipated collections of approximately $50M net. These estimates are forward-looking and subject to significant uncertainty, including collection risk and timing variability. The combined operating company would assume only those liabilities expressly agreed in definitive documentation, currently contemplated to include approximately $5M of ProPhase Labs' existing indebtedness. All other legacy liabilities would remain with ProPhase Labs and would not be obligations of the post-merger entity. The proposed transaction remains subject to due diligence, negotiation and execution of definitive agreements, regulatory approvals, Nasdaq listing requirements, and other customary closing conditions.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。